Comparative Effects of Ephedrine and Norepinephrine on Fetal Acid–Base Status during Cesarean Delivery under Spinal Anesthesia: A Randomized Double-Blind Study

Technical Summary: Comparative Effects of Ephedrine and Norepinephrine on Fetal Acid–Base Status during Cesarean Delivery

Problem Statement
Spinal anesthesia is the standard for cesarean delivery but frequently induces maternal hypotension (occurring in 60–80% of cases) due to sympathetic blockade. This hypotension compromises uteroplacental perfusion, increasing the risk of fetal hypoxia and acidosis. While vasopressors are the cornerstone of management, the choice of agent remains debated. Ephedrine has historically been the first-line agent due to its presumed ability to preserve uteroplacental blood flow; however, it crosses the placenta and may increase fetal metabolic activity, potentially lowering umbilical arterial (UA) pH. Conversely, norepinephrine has emerged as a promising alternative with potent $\alpha$-adrenergic effects and modest $\beta$-activity, potentially offering better hemodynamic stability. Despite its growing use, randomized controlled trials directly comparing the effects of norepinephrine and ephedrine on neonatal metabolic status and fetal acid–base balance remain limited.

Methodology
The authors conducted a prospective, randomized, double-blind, controlled trial at a single center in Türkiye.

• Participants: The study included parturients (ASA I–II, 18–45 years) undergoing elective cesarean delivery under spinal anesthesia. The final analysis population consisted of 102 patients who developed postspinal hypotension (SBP < 80% of baseline) and required vasopressor intervention.
• Intervention: Patients were randomized 1:1 to receive either 5 mg boluses of ephedrine or 5 µg boluses of norepinephrine. Dosing was repeated at 1-minute intervals until blood pressure targets were met.
• Blinding: The study utilized a double-blind design where study medications were prepared by an independent investigator in visually identical syringes. Participants, anesthesiologists, and outcome assessors (pediatricians) were blinded to group allocation.
• Outcomes: The primary outcome was umbilical arterial (UA) pH. Secondary outcomes included UA pCO₂, base excess, lactate levels, Apgar scores, maternal hemodynamic stability (SBP, HR), vasopressor requirements, and adverse events.
• Analysis: Statistical analysis was performed using intention-to-treat principles for the per-protocol population (those requiring treatment). Non-parametric data were analyzed using the Mann–Whitney U test, and repeated-measures ANOVA was used for hemodynamic trends.

Key Results

• Fetal Acid–Base Status: The median UA pH was statistically significantly lower in the norepinephrine group compared to the ephedrine group (7.33 vs. 7.35; P = 0.010). Similarly, UA pCO₂ was higher in the norepinephrine group (45.2 mmHg vs. 40.9 mmHg; P = 0.006), and actual HCO₃⁻ was also higher. However, markers of metabolic status, including base excess (P = 0.828) and lactate concentrations (P = 0.733), were equivalent between groups.
• Clinical Significance of Acidosis: Despite the statistical difference in pH, the incidence of neonatal acidosis (defined as UA pH < 7.20) was low and did not differ significantly between groups (4.0% in norepinephrine vs. 1.9% in ephedrine; P = 0.614).
• Neonatal Outcomes: Apgar scores at 1 and 5 minutes were comparable. Neonatal heart rate was significantly lower in the norepinephrine group (162.7 bpm vs. 169.9 bpm; P = 0.029).
• Maternal Hemodynamics: Both agents effectively managed hypotension with comparable frequencies and durations of hypotensive episodes. However, the ephedrine group required a significantly higher pre-delivery vasopressor dose (P = 0.002) and exhibited higher overall mean SBP values. The incidence of maternal adverse events (nausea, headache, bradycardia) was similar between groups.

Key Contributions
This study provides a direct, head-to-head comparison of norepinephrine and ephedrine in the specific context of treating postspinal hypotension during elective cesarean sections. Its primary contribution is the clarification of fetal metabolic outcomes: while norepinephrine resulted in a statistically lower UA pH and higher pCO₂, these changes did not translate into metabolic acidosis (as evidenced by equivalent base excess and lactate levels) or adverse neonatal clinical outcomes (Apgar scores). The study further characterizes the hemodynamic profiles, noting that norepinephrine achieves blood pressure control with lower total drug volumes and less maternal tachycardia compared to ephedrine.

Significance and Claims
The authors conclude that while norepinephrine is associated with a statistically significant reduction in UA pH compared to ephedrine, the absolute difference is modest and remains within physiological limits. Crucially, the study asserts that this statistical difference does not translate into clinically meaningful differences in neonatal acidosis or immediate neonatal condition.

The paper posits that norepinephrine serves as a suitable alternative to ephedrine for managing postspinal hypotension. It offers comparable maternal hemodynamic stability and fetal safety, with the added benefit of potentially lower vasopressor requirements and reduced maternal tachycardia. The authors emphasize that the observed physiological variations (lower pH, higher pCO₂, lower neonatal HR) likely reflect subtle differences in placental gas exchange and fetal $\beta$-adrenergic exposure rather than overt fetal hypoxia or metabolic compromise. Consequently, the study supports the use of norepinephrine as a clinically acceptable option in standardized obstetric anesthesia practice.